US EditionPublished • loading... • Updated
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients - Alz
Summary by Alzheon | Preserving Future Memories
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients - Alz
Early and Consistent Decreases in P-tau217 Plasma Levels Were Associated with Improvements in Cognition, Function, and Brain Atrophy Measures MCI Subjects Receiving Valiltramiprosate Showed Significant Correlations Between Decreases in Plasma P-tau217 and Improvements on ADAS-Cog (r = 0.28, p = 0.039), CDR-SB (r = 0.38, p = 0.005), and Hippocampal Volume (r
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
